Literature DB >> 23418612

The Reliability of Endoscopic Biopsies in Assessing HER2 Status in Gastric and Gastroesophageal Junction Cancer: A Study Comparing Biopsies with Surgical Samples.

Federica Grillo1, Matteo Fassan, Chiara Ceccaroli, Cinzia Giacometti, Monica Curto, Vittorina Zagonel, Paola Ceppa, Donato Nitti, Carlo Castoro, Roberto Fiocca, Massimo Rugge, Luca Mastracci.   

Abstract

AIM: The aim of this study is to validate the accuracy of HER2 assessment on biopsies by comparing matched biopsy/surgical material from the same patients.
METHODS: HER2 status was evaluated by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) in 103 cases of gastric and gastroesophageal junction cancers in coupled biopsy and surgical material. RESULT: Complete concordance between IHC and FISH results on biopsy versus surgical samples was noted in 80% and 95% of cases, respectively. At comprehensive comparison, including IHC and FISH data on biopsy and surgical samples, 89% of biopsies were predictive of HER2 status in surgical samples, whereas 11% showed variable inconsistencies. The majority of these (10 of 12 cases) showed IHC score 0/1+ on biopsy but were all IHC positive and amplified at surgery; in particular, three (3 of 35; 8.5%) IHC score 0 and four (4 of 16; 25%) IHC score 1+ cases were FISH amplified on biopsy material also, whereas the remaining three cases were FISH non-amplified on biopsy. The percentage of cases, which were FISH amplified with IHC score 1+ or 2+ on biopsies, were similar (25% and 33%, respectively) and they also shared a similar grade of amplification. These data suggest that both IHC score 1+ and 2+ on biopsy material represent "equivocal cases" that may merit further investigation.
CONCLUSIONS: The predictive value of HER2 IHC in biopsies is high. FISH analysis should be considered for IHC score 2+ and 1+ biopsy cases. Approximately 8% of cases will not be accurately predicted by biopsy evaluation.

Entities:  

Year:  2013        PMID: 23418612      PMCID: PMC3573649          DOI: 10.1593/tlo.12334

Source DB:  PubMed          Journal:  Transl Oncol        ISSN: 1936-5233            Impact factor:   4.243


  32 in total

1.  Localization of a novel v-erbB-related gene, c-erbB-2, on human chromosome 17 and its amplification in a gastric cancer cell line.

Authors:  S Fukushige; K Matsubara; M Yoshida; M Sasaki; T Suzuki; K Semba; K Toyoshima; T Yamamoto
Journal:  Mol Cell Biol       Date:  1986-03       Impact factor: 4.272

2.  Gastric carcinoma. A pathobiological classification.

Authors:  S C Ming
Journal:  Cancer       Date:  1977-06       Impact factor: 6.860

Review 3.  HER-2/neu (c-erb-B2) gene and protein in breast cancer.

Authors:  J S Ross; J A Fletcher
Journal:  Am J Clin Pathol       Date:  1999-07       Impact factor: 2.493

Review 4.  The ErbB receptors and their ligands in cancer: an overview.

Authors:  N Normanno; C Bianco; L Strizzi; M Mancino; M R Maiello; A De Luca; F Caponigro; D S Salomon
Journal:  Curr Drug Targets       Date:  2005-05       Impact factor: 3.465

5.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

Authors:  Antonio C Wolff; M Elizabeth H Hammond; Jared N Schwartz; Karen L Hagerty; D Craig Allred; Richard J Cote; Mitchell Dowsett; Patrick L Fitzgibbons; Wedad M Hanna; Amy Langer; Lisa M McShane; Soonmyung Paik; Mark D Pegram; Edith A Perez; Michael F Press; Anthony Rhodes; Catharine Sturgeon; Sheila E Taube; Raymond Tubbs; Gail H Vance; Marc van de Vijver; Thomas M Wheeler; Daniel F Hayes
Journal:  J Clin Oncol       Date:  2006-12-11       Impact factor: 44.544

Review 6.  Chemotherapy for metastatic gastric cancer: past, present, and future.

Authors:  Atsushi Ohtsu
Journal:  J Gastroenterol       Date:  2008-05-06       Impact factor: 7.527

7.  HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing.

Authors:  Josef Rüschoff; Manfred Dietel; Gustavo Baretton; Susanne Arbogast; Axel Walch; Geneviéve Monges; Marie-Pierre Chenard; Frédérique Penault-Llorca; Iris Nagelmeier; Werner Schlake; H Höfler; H H Kreipe
Journal:  Virchows Arch       Date:  2010-07-28       Impact factor: 4.064

Review 8.  HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target.

Authors:  C Gravalos; A Jimeno
Journal:  Ann Oncol       Date:  2008-04-25       Impact factor: 32.976

9.  HER2 status in gastro-oesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two in situ hybridization methods (FISH and SISH).

Authors:  James E Boers; Harriëtte Meeuwissen; Natalie Methorst
Journal:  Histopathology       Date:  2011-02-16       Impact factor: 5.087

10.  HER2 expression in gastric cancer: Rare, heterogeneous and of no prognostic value - conclusions from 924 cases of two independent series.

Authors:  Heike Grabsch; Shivan Sivakumar; Sally Gray; Helmut E Gabbert; Wolfram Müller
Journal:  Cell Oncol       Date:  2010       Impact factor: 6.730

View more
  18 in total

1.  HLA-G expression in gastric carcinoma: clinicopathological correlations and prognostic impact.

Authors:  Giuseppe Murdaca; Paola Calamaro; Francesca Lantieri; Simona Pigozzi; Luca Mastracci; Federica Grillo; Ottavia Magnani; Paola Ceppa; Francesco Puppo; Roberto Fiocca
Journal:  Virchows Arch       Date:  2018-05-29       Impact factor: 4.064

Review 2.  HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology.

Authors:  Angela N Bartley; Mary Kay Washington; Christina B Ventura; Nofisat Ismaila; Carol Colasacco; Al B Benson; Alfredo Carrato; Margaret L Gulley; Dhanpat Jain; Sanjay Kakar; Helen J Mackay; Catherine Streutker; Laura Tang; Megan Troxell; Jaffer A Ajani
Journal:  Am J Clin Pathol       Date:  2016-11-14       Impact factor: 2.493

3.  HER2/neu as target in gastric adenocarcinoma.

Authors:  Bulent Cetin; Ahmet Ozet
Journal:  Transl Gastroenterol Hepatol       Date:  2016-07-22

4.  Clinicopathological features and endoscopic findings of HER2-positive gastric cancer.

Authors:  Yasuhiro Oono; Takeshi Kuwata; Kenji Takashima; Yusuke Yoda; Hiroaki Ikematsu; Kohei Shitara; Takahiro Kinoshita; Tomonori Yano
Journal:  Surg Endosc       Date:  2018-03-02       Impact factor: 4.584

5.  Prognosis significance of HER2 status and TACC1 expression in patients with gastric carcinoma.

Authors:  Jing Lv; Ya-sai Yao; Fei Zhou; Li-kun Zhuang; Ru-yong Yao; Jun Liang; Wen-sheng Qiu; Lu Yue
Journal:  Med Oncol       Date:  2014-10-09       Impact factor: 3.064

6.  HER2 testing in paired biopsy and excision specimens of gastric cancer: the reliability of the scoring system and the clinicopathological factors relevant to discordance.

Authors:  Shih-Chiang Huang; Kwai-Fong Ng; Shang-En Lee; Kuang-Hua Chen; Ta-Sen Yeh; Tse-Ching Chen
Journal:  Gastric Cancer       Date:  2014-12-17       Impact factor: 7.370

7.  HER2 overexpression/amplification status in colorectal cancer: a comparison between immunohistochemistry and fluorescence in situ hybridization using five different immunohistochemical scoring criteria.

Authors:  Qi Sun; Qi Li; Fuping Gao; Hongyan Wu; Yao Fu; Jun Yang; Xiangshan Fan; Xiaobin Cui; Xiaohong Pu
Journal:  J Cancer Res Clin Oncol       Date:  2022-08-26       Impact factor: 4.322

8.  Deviating HER2 test results in gastric cancer: analysis from the prospective multicenter VARIANZ study.

Authors:  Katharina Kolbe; Ivonne Haffner; Katrin Schierle; Dieter Maier; Birgitta Geier; Birgit Luber; Hendrik Bläker; Christian Wittekind; Florian Lordick
Journal:  J Cancer Res Clin Oncol       Date:  2022-08-27       Impact factor: 4.322

Review 9.  HER2 heterogeneity in gastric/gastroesophageal cancers: From benchside to practice.

Authors:  Federica Grillo; Matteo Fassan; Francesca Sarocchi; Roberto Fiocca; Luca Mastracci
Journal:  World J Gastroenterol       Date:  2016-07-14       Impact factor: 5.742

10.  Minimum biopsy set for HER2 evaluation in gastric and gastro-esophageal junction cancer.

Authors:  Irene Gullo; Federica Grillo; Luca Molinaro; Matteo Fassan; Annalisa De Silvestri; Carmine Tinelli; Massimo Rugge; Roberto Fiocca; Luca Mastracci
Journal:  Endosc Int Open       Date:  2015-02-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.